MESA LABORATORIES INC /CO/
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
MLAB$136.91+7.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
M****esa Laboratories, Inc.**
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income | $7,171 | $7,218 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation of property, plant and equipment | 2,505 | 2,719 |
| Amortization of intangible assets | 8,701 | 9,087 |
| Stock-based compensation expense | 5,736 | 7,693 |
| Foreign currency adjustments | 503 | (6,081) |
| Other | 1,361 | 2,878 |
| Cash from changes in operating assets and liabilities: | ||
| Accounts receivable, net | 4,683 | 1,740 |
| Inventories | (1,831) | (4,056) |
| Prepaid expenses and other assets | (2,072) | (823) |
| Accounts payable | (54) | (997) |
| Accrued liabilities and taxes payable | (7,202) | (8,505) |
| Unearned revenues | (669) | (758) |
| Net cash provided by operating activities | 18,832 | 10,115 |
| Cash flows from investing activities: | ||
| Purchases of property, plant and equipment | (946) | (2,101) |
| Net cash (used in) investing activities | (946) | (2,101) |
| Cash flows from financing activities: | ||
| Proceeds from debt borrowings | 10,000 | 107,500 |
| Debt repayments | (30,062) | (110,875) |
| GKE acquisition-related holdback payment | - | (9,555) |
| Dividends paid | (1,782) | (1,755) |
| Other financing, net | (968) | (1,625) |
| Net cash (used in) financing activities | (22,812) | (16,310) |
| Effect of exchange rate changes on cash and cash equivalents | 310 | 1,397 |
| Net (decrease) in cash and cash equivalents | (4,616) | (6,899) |
| Cash and cash equivalents at beginning of period | 26,928 | 27,321 |
| Cash and cash equivalents at end of period | $22,312 | $20,422 |
See accompanying notes to Condensed Consolidated Financial Statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.